Acticor Biotech SAS (ALACT.PA)
| Previous close | 0.5400 |
| Open | 0.5100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4800 - 0.5100 |
| 52-week range | 0.2700 - 6.0000 |
| Volume | |
| Avg. volume | 81,935 |
| Market cap | 7.445M |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.50 |
Business WireActicor Biotech Announces the Conclusions of the Interim Futility Analysis in the GREEN Study
PARIS, July 26, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces the conclusions of the futility analysis of the phase 2/3 GREEN study evaluating glenzocimab as an adjunct to mechanical thrombectomy in acute ischemic stroke.
Business WireActicor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
PARIS, July 18, 2024--Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.
Business WireActicor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of June 30, 2024
PARIS, July 17, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today discloses the total number of voting rights and shares as of June 30, 2024 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).
